TW202242412A - 檢查罹患前列腺癌之可能性的方法 - Google Patents

檢查罹患前列腺癌之可能性的方法 Download PDF

Info

Publication number
TW202242412A
TW202242412A TW110148710A TW110148710A TW202242412A TW 202242412 A TW202242412 A TW 202242412A TW 110148710 A TW110148710 A TW 110148710A TW 110148710 A TW110148710 A TW 110148710A TW 202242412 A TW202242412 A TW 202242412A
Authority
TW
Taiwan
Prior art keywords
prostate cancer
ions
group
cyclohexenone
phenol
Prior art date
Application number
TW110148710A
Other languages
English (en)
Chinese (zh)
Inventor
尾添淳文
小林健太郎
高橋康彦
松永光平
佐藤孝明
水谷陽一
Original Assignee
日商住友化學股份有限公司
國立研究開發法人產業技術總合研究所
學校法人藍野大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商住友化學股份有限公司, 國立研究開發法人產業技術總合研究所, 學校法人藍野大學 filed Critical 日商住友化學股份有限公司
Publication of TW202242412A publication Critical patent/TW202242412A/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7206—Mass spectrometers interfaced to gas chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8624—Detection of slopes or peaks; baseline correction
    • G01N30/8631—Peaks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
TW110148710A 2021-01-07 2021-12-24 檢查罹患前列腺癌之可能性的方法 TW202242412A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021001676 2021-01-07
JP2021-001676 2021-01-07

Publications (1)

Publication Number Publication Date
TW202242412A true TW202242412A (zh) 2022-11-01

Family

ID=82357872

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110148710A TW202242412A (zh) 2021-01-07 2021-12-24 檢查罹患前列腺癌之可能性的方法

Country Status (7)

Country Link
US (1) US20240085400A1 (https=)
EP (1) EP4276456A4 (https=)
JP (1) JP7769179B2 (https=)
CN (1) CN116783484A (https=)
AU (1) AU2021417970A1 (https=)
TW (1) TW202242412A (https=)
WO (1) WO2022149487A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515270A (ja) * 2009-12-22 2013-05-02 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝学的プロファイリング
US20130217647A1 (en) * 2010-07-28 2013-08-22 Metabolon, Inc. Biomarkers for Prostate Cancer and Methods Using the Same
US20160025734A1 (en) * 2014-07-23 2016-01-28 Children's Medical Center Corporation Use of urinary protein biomarkers to distinguish between neoplastic and non-neoplastic disease of the prostate
JP2017203649A (ja) * 2016-05-09 2017-11-16 国立大学法人大阪大学 前立腺がん判定方法
CN108344830B (zh) * 2017-01-22 2020-10-16 中国科学院大连化学物理研究所 用于诊断前列腺癌的尿样组合标志物及检测试剂盒
US10908162B2 (en) * 2017-10-27 2021-02-02 The Board Of Regents Of The University Of Texas System Methods related to volatile compounds in genitourinary cancers

Also Published As

Publication number Publication date
EP4276456A4 (en) 2025-02-26
CN116783484A (zh) 2023-09-19
JP7769179B2 (ja) 2025-11-13
AU2021417970A1 (en) 2023-07-27
AU2021417970A9 (en) 2024-05-16
WO2022149487A1 (ja) 2022-07-14
JPWO2022149487A1 (https=) 2022-07-14
EP4276456A1 (en) 2023-11-15
US20240085400A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
Shigeyama et al. Identification of volatile metabolites in human saliva from patients with oral squamous cell carcinoma via zeolite-based thin-film microextraction coupled with GC–MS
Jeddi et al. Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer
JP2022091763A (ja) 肝疾患関連バイオマーカーおよびその使用方法
Xu et al. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer
EP2580596A1 (en) Methods to diagnose liver diseases
US20100273666A1 (en) Methods of analyzing wound samples
EP2705164A1 (en) A method of diagnosing neoplasms
Fischer et al. Assessment of mucosal integrity by quantifying neutrophil granulocyte influx in murine models of acute intestinal injury
Zivancevic-Simonovic et al. Transforming growth factor beta 1 (TGF-β 1) in COVID-19 patients: relation to platelets and association with the disease outcome
Igoh et al. Identification and evaluation of potential forensic marker proteins in vaginal fluid by liquid chromatography/mass spectrometry
KR20190109422A (ko) 방법, 어레이 및 그 용도
Delmonico et al. Proteomic profile of saliva and plasma from women with impalpable breast lesions
CA3202252A1 (en) Biomarkers signature(s) for the prevention and early detection of gastric cancer
Palmirotta et al. Impact of preanalytical handling and timing for peripheral blood mononuclear cells isolation and RNA studies: the experience of the Interinstitutional Multidisciplinary BioBank (BioBIM)
CN117802221A (zh) 用于筛查高原头痛易感者的microRNA分子标志物
Marucci et al. Oncocytic glioblastoma: a glioblastoma showing oncocytic changes and increased mitochondrial DNA copy number
Negrei et al. Investigation relevance of methotrexate polyglutamates in biological systems by high performance liquid chromatography
TW202242412A (zh) 檢查罹患前列腺癌之可能性的方法
JP2008533979A (ja) 生体細胞中の時間依存的な発現を防止するための試薬及び方法
EP3388448B1 (en) Marker for pancreatic cancer and intraductal papillary mucinous tumors
EP2772759B1 (en) Composition for diagnosis of lung cancer
Rostampour et al. Total antioxidant capacity, lipid peroxidation, thiol group and catalase activity in patients with kidney stone
Wei et al. A proteomic analysis of transplanted liver in a rat model of chronic rejection
Komarevtseva et al. Alfa-1-Antitrypsin Predicts Severe COVID-19, Gastric and Renal Cancer in Conditions of Hyperglycemia
Hayward et al. Post‐collection, pre‐measurement variables affecting VEGF levels in urine biospecimens